A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%
Phase of Trial: Phase III
Latest Information Update: 25 Mar 2018
At a glance
- Drugs Cemiplimab (Primary) ; Ipilimumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 12 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Feb 2018 According to a Sanofi media release, company plans to initiate this study in Q1 2018.
- 23 Jan 2018 Status changed from planning to not yet recruiting.